Blog Read the latest perspectives from our team of subject matter experts and others Ribbon Health and H1: Merging Missions to Transform HealthcareOn January 8th, we celebrated an exciting milestone: Ribbon Health merged with H1! This union represents a significant leap toward achieving our shared vision of transforming healthcare by ensuring… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development Global Impact HCP Volunteers KOL Engagement Provider Data Research Post Industries:Commercialization Global Impact Payors Pharmaceutical & Biotechnology Provider Data Research Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchTrials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentSix Possible Implications of Biden’s Executive Order on AI for Life SciencesThe life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentWhy Clinical Trial Success Criteria Matters: 5 Essential QuestionsAs the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentOptimizing Clinical Data Registries: Opportunities for Diversity and FeasibilityIn an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical… Continue reading → Read the articleno Artificial IntelligenceEvaluating an AI Product in Life SciencesThe life sciences industry, characterized by stringent regulations, vast data sets, and the critical nature of its decisions, is increasingly turning to Artificial Intelligence (AI) for solutions. AI has the… Continue reading → Read the articleno‹12345›»
